The Myelofibrosis market across the seven major markets (7MM), including the United States, EU4, the United Kingdom, and Japan, is anticipated to witness substantial expansion during the forecast period. The market is projected to grow from nearly USD 2,602 million in 2025 to approximately USD 5,638 million by 2034, registering a CAGR of 9.00%. Rising adoption of targeted therapies, increasing prevalence of myeloproliferative neoplasms, growing awareness regarding precision diagnostics, and the launch of novel JAK inhibitors are key growth drivers. Additionally, continuous advancements in molecular testing and increasing investments in hematologic oncology are strengthening the overall Myelofibrosis market insight landscape globally.
Explore evolving therapeutic innovations shaping the future of the Myelofibrosis market across major healthcare economies.
Myelofibrosis Overview
Myelofibrosis is a rare chronic blood cancer characterized by the progressive formation of fibrous scar tissue within the bone marrow, impairing its ability to produce healthy blood cells. It belongs to a broader category of disorders known as myeloproliferative neoplasms (MPNs). Myelofibrosis may develop independently as primary myelofibrosis or evolve secondary to polycythemia vera or essential thrombocythemia. Common genetic mutations associated with the disease include JAK2, CALR, and MPL mutations. Clinical manifestations often include anemia, splenomegaly, fatigue, night sweats, cachexia, thrombosis, bone pain, bleeding complications, and constitutional symptoms that significantly impact patient quality of life.
Myelofibrosis Diagnosis
Diagnosis of Myelofibrosis involves a comprehensive evaluation using blood tests, bone marrow aspiration, bone marrow biopsy, molecular testing, and mutation-enhanced morphologic analysis. Bone marrow testing remains the gold standard for confirming fibrosis and assessing marrow architecture. Molecular diagnostic methods identify key mutations including JAK2, CALR, and MPL, supporting disease classification and therapeutic planning. Cytogenetic and biomarker analyses are increasingly integrated into clinical practice to optimize risk stratification and personalized treatment approaches. The growing adoption of advanced diagnostic technologies continues to shape positive Myelofibrosis market trends across major healthcare systems.
Myelofibrosis Treatment
Treatment strategies for Myelofibrosis focus on symptom management, improving survival outcomes, and reducing disease burden. Allogeneic stem cell transplantation remains the only potentially curative option; however, it is limited to selected eligible patients due to high treatment-associated risks. Current therapeutic management primarily relies on JAK inhibitors and supportive therapies.
Approved therapies include:
- JAKAFI / JAKAVI (ruxolitinib)
- INREBIC
- VONJO
- OJJAARA
Low-risk patients are generally managed using interferon alfa, hydroxyurea, or ruxolitinib, whereas intermediate- and high-risk patients often receive advanced JAK inhibitor therapies or stem cell transplantation. Ongoing innovation in targeted therapeutics continues to enhance the competitive dynamics of the Myelofibrosis market research ecosystem.
Myelofibrosis Epidemiology
The epidemiology segment of the Myelofibrosis market insight report evaluates historical and forecasted patient populations across the 7MM from 2020 to 2034. The report analyzes diagnosed prevalent cases, risk-based segmentation, molecular alterations, and age-specific distribution trends.
Key epidemiological findings include:
- Total prevalent cases in the 7MM reached nearly 55,900 in 2024.
- Prevalence is expected to increase steadily during the forecast period.
- Germany accounted for the highest diagnosed prevalence among EU4 and the UK.
- High-risk myelofibrosis represented the largest patient segment in the US.
- Primary myelofibrosis contributed approximately 75% of US cases in 2024.
- Patients aged ≥70 years represented the largest age group in the US.
- JAK2 mutations accounted for nearly 60% of total US cases.
Growing prevalence and increasing disease awareness are expected to accelerate future Myelofibrosis market trends globally.
Marketed Myelofibrosis Drugs
- JAKAFI / JAKAVI (ruxolitinib) – Incyte / Novartis
Ruxolitinib is a kinase inhibitor targeting JAK signaling pathways responsible for abnormal blood cell production in myelofibrosis. The therapy significantly reduces splenomegaly and constitutional symptoms while improving overall patient outcomes. It received US FDA approval in 2011 for intermediate- and high-risk myelofibrosis and later secured approvals across Europe and Japan. The therapy remains a dominant revenue contributor in the global Myelofibrosis market.
- INREBIC – Bristol Myers Squibb
Fedratinib is an oral JAK2-selective kinase inhibitor developed for intermediate-2 and high-risk primary or secondary myelofibrosis. The therapy inhibits STAT3/5 signaling pathways, suppressing malignant cell proliferation and inducing apoptosis. Despite demonstrating efficacy comparable to ruxolitinib, fedratinib carries a black box warning associated with encephalopathy risk. Nevertheless, its approval expanded therapeutic competition and strengthened innovation within the Myelofibrosis market research domain.
Emerging Myelofibrosis Drugs
- XPOVIO – Karyopharm Therapeutics
Selinexor is an oral Selective Inhibitor of Nuclear Export (SINE) compound targeting XPO1-mediated nuclear export pathways. By restoring tumor suppressor protein function, selinexor selectively induces apoptosis in malignant cells. The therapy received Orphan Drug Designation and Fast Track Designation from the US FDA for myelofibrosis treatment. Ongoing Phase II and Phase III SENTRY studies are expected to significantly influence future Myelofibrosis market trends.
- RYTELO – Geron Corporation
Imetelstat is a telomerase inhibitor designed to suppress malignant stem and progenitor cells responsible for disease progression in blood cancers. The therapy has demonstrated disease-modifying activity in clinical trials and may offer long-term clinical benefits for patients with advanced myelofibrosis. Initial data from the IMproveMF study are expected in 2026.
- REBLOZYL – Bristol Myers Squibb
Luspatercept is an erythroid maturation agent developed to address anemia associated with myelofibrosis. The therapy modulates late-stage erythrocyte precursor differentiation within the bone marrow microenvironment. Phase III clinical data expected in 2025 could support expanded therapeutic applications and improve anemia management strategies.
Myelofibrosis Market Outlook
The Myelofibrosis market continues to evolve rapidly with increasing therapeutic innovation and growing clinical emphasis on disease-modifying treatments. Historically, treatment options remained limited, with stem cell transplantation representing the only curative approach. However, the introduction of JAK inhibitors transformed disease management standards.
JAKAFI remained the dominant therapy for years until the approval of INREBIC in 2019. Subsequently, VONJO gained approval in 2022 for patients with severe thrombocytopenia, while OJJAARA received approval in 2023 for addressing anemia, splenomegaly, and constitutional symptoms simultaneously.
Despite significant progress, current therapies do not provide complete cures, creating substantial unmet clinical needs. Consequently, pharmaceutical companies are actively investigating novel mechanisms, combination therapies, and next-generation targeted agents. Emerging candidates such as Navtemadlin (KRT-232), Selinexor, Imetelstat, Pelabresib, and Luspatercept are expected to redefine future treatment paradigms.
- Expanded clinical evaluation of combination JAK inhibitor regimens.
- Increasing utilization of molecular diagnostics for personalized therapy selection.
- Advancements in anemia-focused therapies targeting transfusion dependency.
- Accelerated orphan drug approvals and fast-track designations.
- Rising investment in disease-modifying and fibrosis-targeted therapies.
Market insights indicate that the total 7MM market reached approximately USD 2.2 billion in 2024 and is expected to expand substantially through 2034. The United States represented the largest regional market, followed by Germany within Europe. Among currently marketed products, ruxolitinib is projected to maintain the highest revenue contribution during the forecast period. Continuous innovation and robust late-stage pipelines are expected to sustain positive Myelofibrosis market research momentum worldwide.
Discover comprehensive Myelofibrosis market research insights driving next-generation treatment advancements and commercial opportunities.
Key Companies Developing Myelofibrosis Therapies
- Pharmaxis
- Keros Therapeutics
- Bristol Myers Squibb
- Ascentage Pharma Group
- Sumitomo Pharma Oncology
- Galecto Biotech
- Actuate Therapeutics
- Karyopharm Therapeutics
- AbbVie
- Chia Tai Tianqing Pharmaceutical Group
- Taiga Biotechnologies
- Rigel Pharmaceuticals
- And others.
Conclusion
The global Myelofibrosis market is positioned for substantial growth owing to increasing disease prevalence, rising awareness, and accelerating therapeutic innovation. Advancements in molecular diagnostics, next-generation JAK inhibitors, and disease-modifying agents are transforming treatment approaches and improving patient outcomes. Emerging pipeline candidates and expanding regulatory support continue to strengthen overall Myelofibrosis market insight and commercialization opportunities.
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharmaceutical companies by providing comprehensive end-to-end solutions to improve their performance. It also offers healthcare consulting services that leverage market analysis to accelerate business growth and overcome challenges with practical approaches.
Media contact
Name: Abhishek kumar
E-mail:abhishek@delveinsight.com
